Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Liver Int ; 37(1): 141-147, 2017 01.
Article in English | MEDLINE | ID: mdl-27375263

ABSTRACT

BACKGROUND & AIMS: Excessive intestinal gas and liver steatosis are frequent sonographic findings. Both of these appear to be caused by variations of the gut microflora. We assessed the relationship between ultrasonographic detection of intestinal gas and liver steatosis. METHODS: This study included 204 consecutive patients (99 male; mean age 53.0 ± 15.6 years), who underwent ultrasonography for abdominal complaints or follow-up of benign lesions. Body mass index, biochemical liver markers, sonographic presence of liver steatosis and/or degree of intestinal gas interfering with the examination were collected. Both sonographic findings were assessed based on standardized criteria. The association between liver steatosis and intestinal gas was evaluated by means of univariate and multivariate analyses. RESULTS: Eighty (39.2%) of patients showed moderate to large amounts of gas preventing an accurate evaluation of the liver or pancreas and 90 (44.1%) had liver steatosis. A significant correlation between the degree of intestinal gas and liver steatosis both in obese (r=.603; P<.001) and in nonobese patients (r=.555; P<.001) was found. Univariate analysis showed that intestinal gas, body mass index, aspartate transaminase, alanine transaminase, gamma-GT, age and sex were predictors of liver steatosis; only intestinal gas (OR 7.4; 95% CI 3.4-16.1) and body mass index (OR; 1.4, 95% CI 1.2-1.5), however, were independent predictors at multivariate analysis. The presence of excessive gas was also significantly correlated with liver steatosis coupled with elevated ALT (P = .001). CONCLUSION: This study shows a significant correlation between excessive intestinal gas and liver steatosis. The reasons of this finding and its clinical implications remain to be defined.


Subject(s)
Fatty Liver/physiopathology , Flatulence/physiopathology , Liver/physiopathology , Obesity/complications , Adult , Aged , Body Mass Index , Fatty Liver/diagnostic imaging , Female , Flatulence/diagnostic imaging , Gastrointestinal Motility , Humans , Italy , Liver/diagnostic imaging , Logistic Models , Male , Middle Aged , Multivariate Analysis , Prospective Studies , Severity of Illness Index , Ultrasonography , gamma-Glutamyltransferase/metabolism
2.
Expert Opin Ther Targets ; 18(12): 1449-59, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25200104

ABSTRACT

INTRODUCTION: Bile acids, the end product of cholesterol metabolism, are signaling molecules. The farnesoid X receptor (FXR) is a bile acid sensor and is part of a network of nuclear receptors that regulate bile acid homeostasis. In addition to FXR, bile acids activate other nuclear receptors (CAR, PXR and VDR), cell surface receptors including the G protein-coupled bile acid receptor 1 (GP-BAR1/TGR5), muscarinic receptor and calcium-gated potassium channels. AREAS COVERED: The semisynthetic bile acid derivative 6-ethyl chenodeoxycholic acid (6-ECDCA, INT-747 later christened obeticholic acid) is a dual FXR/GP-BAR1 ligand that attenuates bile flow impairment in cholestasis induced by 17ß-estradiol; a model of pregnancy-induced cholestasis. Phase II trials with this agent in early stage primary biliary cirrhosis have shown beneficial effects on surrogate markers of damage progression, specifically alkaline phosphatase, with a dose-dependent itching being the most severe and common side effect (up to 70% of patients) leading to therapy discontinuation in 38% of patients. GP-BAR1 activation in the skin triggers itching, thus providing a molecular explanation for this side effect. EXPERT OPINION: While the role of FXR activation in treating severe cholestasis needs confirmation, the activation of GP-BAR1 is likely involved in pruritus development that associates with clinical use of dual FXR/GP-BAR1 ligands. FXR antagonist could be an interesting opportunity for treatment of severe/obstructive cholestasis.


Subject(s)
Cholestasis/drug therapy , Cholestasis/metabolism , Drug Delivery Systems/methods , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Bile Acids and Salts/antagonists & inhibitors , Bile Acids and Salts/metabolism , Clinical Trials as Topic/methods , Drug Delivery Systems/trends , Humans , Lipid Metabolism/drug effects , Lipid Metabolism/physiology , Receptors, Cytoplasmic and Nuclear/agonists
4.
Rev Esp Enferm Dig ; 104(4): 203-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22537369

ABSTRACT

Chronic hepatitis is a frequent pathologic condition encountered in both dogs and humans; however, in the latter etiologic factors are usually searched and found that allow targeted therapeutic approaches, whereas in dogs this is less frequent. This review will take into consideration chronic hepatitis in dogs, and discuss differences and similarities between the two species with respect to this disease.


Subject(s)
Dog Diseases , Hepatitis, Chronic/veterinary , Animals , Dog Diseases/diagnosis , Dog Diseases/etiology , Dogs , Hepatitis, Chronic/diagnosis , Hepatitis, Chronic/etiology , Humans
5.
Rev. esp. enferm. dig ; 104(4): 203-209, abr. 2012. ilus
Article in English | IBECS | ID: ibc-100194

ABSTRACT

Chronic hepatitis is a frequent pathologic condition encountered in both dogs and humans; however, in the latter etiologic factors are usually searched and found that allow targeted therapeutic approaches, whereas in dogs this is less frequent. This review will take into consideration chronic hepatitis in dogs, and discuss differences and similarities between the two species with respect to this disease(AU)


Subject(s)
Humans , Animals , Male , Female , Adult , Dogs , Hepatitis, Chronic/diagnosis , Hepatitis, Chronic/therapy , Hepatitis/etiology , Hepatitis/physiopathology , Hepatitis, Animal/diagnosis , Hepatitis, Animal/etiology , Hepatitis, Chronic/physiopathology , Hepatitis, Chronic/veterinary
6.
Rev Esp Enferm Dig ; 103(7): 366-72, 2011 Jul.
Article in English, Spanish | MEDLINE | ID: mdl-21770683

ABSTRACT

Apart from inflammatory bowel diseases (IBD), there are several other form of colitis that may resemble macroscopically IBD, entering the differential diagnosis. These forms are represented by infectious colitis, ischemic colitis, pseudomembranous colitis, colitis related to diverticular disease, colitis related to mucosal prolapse, drug colitis, allergic colitis, and microscopic colitis. However, to distinguish between these forms is not always easy, and it frequently requires a strict interrelationship between the pathologist and the gastroenterologist. Here we discuss the more frequent forms of non- inflammatory bowel diseases colitides, trying to give useful hints for helping the clinician to better understand the extent to which the pathologist is called to give a definitive response in the differential diagnosis of these entities.


Subject(s)
Colitis/diagnosis , Colitis/pathology , Colitis, Collagenous/diagnosis , Colitis, Collagenous/pathology , Colitis, Ischemic/diagnosis , Colitis, Ischemic/pathology , Diagnosis, Differential , Diverticulitis, Colonic/diagnosis , Diverticulitis, Colonic/pathology , Enterocolitis, Pseudomembranous/diagnosis , Enterocolitis, Pseudomembranous/pathology , Humans , Hypersensitivity/complications , Infections/complications , Intestinal Mucosa/pathology
7.
Diabetes Care ; 34(9): 1946-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21788625

ABSTRACT

OBJECTIVE: To compare the effects of a novel soy germ-enriched pasta, containing isoflavone aglycons, with conventional pasta on endothelial function and cardiovascular risk markers in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: This randomized controlled double-blind crossover study compared one serving/day of soy germ pasta and conventional pasta for 8 weeks for effects on brachial artery flow-mediated vasodilation, blood pressure, plasma lipids, oxidized LDL cholesterol, 8-iso-PGF2α, total antioxidant capacity (TAC), glutathione (GSH), and homocysteine. RESULTS: Isoflavone-enriched pasta significantly improved arterial stiffness (P = 0.005) and reduced systolic (P = 0.026) and diastolic (P = 0.017) blood pressures. Plasma TAC increased (P = 0.0002), oxidized LDL cholesterol decreased (P = 0.009), 8-iso-PGF2α decreased (P = 0.001), GSH levels increased (P = 0.0003), and homocysteine decreased (P = 0.009) consistent with a reduction in oxidative stress. No significant changes were observed with conventional pasta. CONCLUSIONS: Pasta enriched with biologically active isoflavone aglycons improved endothelial function and had beneficial effects on cardiovascular risk markers in patients with T2D.


Subject(s)
Diabetes Mellitus, Type 2/diet therapy , Diabetes Mellitus, Type 2/metabolism , Food , Glycine max/chemistry , Aged , Blood Pressure/drug effects , Cross-Over Studies , Diabetes Mellitus, Type 2/blood , Double-Blind Method , Endothelium, Vascular/drug effects , Female , Humans , Isoflavones/blood , Isoflavones/pharmacology , Male , Middle Aged , Oxidative Stress/drug effects
8.
Rev. esp. enferm. dig ; 103(7): 366-372, jul. 2011. tab, ilus
Article in Spanish | IBECS | ID: ibc-90593

ABSTRACT

Apart from inflammatory bowel diseases (IBD), there are several other form of colitis that may resemble macroscopically IBD, entering the differential diagnosis. These forms are represented by infectious colitis, ischemic colitis, pseudomembranous colitis, colitis related to diverticular disease, colitis related to mucosal prolapse, drug colitis, allergic colitis, and microscopic colitis. However, to distinguish be - tween these forms is not always easy, and it frequently requires a strict interrelationship between the pathologist and the gastroenterologist. Here we discuss the more frequent forms of non- inflammatory bowel diseases colitides, trying to give useful hints for helping the clinician to better understand the extent to which the pathologist is called to give a definitive response in the differential diagnosis of these entities(AU)


Subject(s)
Humans , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/diagnosis , Inflammatory Bowel Diseases/surgery , Enterocolitis, Pseudomembranous/complications , Enterocolitis, Pseudomembranous/diagnosis , Inflammatory Bowel Diseases/physiopathology , Inflammatory Bowel Diseases
9.
Dig Liver Dis ; 43(9): 703-6, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21482208

ABSTRACT

BACKGROUND: Bowel ultrasound has been shown to be a useful tool to evaluate patients with inflammatory bowel disease, especially Crohn's disease. However, such data are still scarce in ulcerative colitis patients. AIMS: To establish the value of bowel ultrasound in moderate to severe ulcerative colitis patients, and compare these data with endoscopic findings. PATIENTS AND METHODS: Endoscopic, ultrasound and C-reactive protein data from 51 patients with moderate to severe ulcerative colitis observed during a 3-year period were retrospectively obtained and analysed. RESULTS: All patients displayed pathological thickness (>4 mm) of the colon wall. This value strongly correlated with C-reactive protein values (p=0.0001) and the endoscopic score (p<0.0001). Also, a strong correlation (p<0.0001) was found between CRP values and endoscopic score. CONCLUSIONS: Bowel ultrasound, in expert hands, may represent a useful adjunctive (or first line) tool for the evaluation of patients with moderate to severe ulcerative colitis.


Subject(s)
Colitis, Ulcerative/diagnostic imaging , Colitis, Ulcerative/pathology , Colon/diagnostic imaging , Colon/pathology , Colonoscopy , Adolescent , Adult , Aged , C-Reactive Protein/metabolism , Colitis, Ulcerative/metabolism , Female , Humans , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Ultrasonography , Young Adult
10.
Thromb Res ; 126(1): 12-7, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20051286

ABSTRACT

The dose of warfarin needed to obtain a therapeutic anticoagulation level varies widely among patients and can undergo abrupt changes for unknown reasons. Drug interactions and genetic factors may partially explain these differences. Intestinal flora produces vitamin K2 (VK2) and patients with small intestinal bacterial overgrowth (SIBO) rarely present reduced INR values due to insufficient dietary vitamin K. The present study was undertaken to investigate whether SIBO occurrence may affect warfarin dose requirements in anticoagulated patients. Based on their mean weekly dose of warfarin while on stable anticoagulation, 3 groups of 10 patients each were defined: low dose (LD, or=70 mg/wk). Each patient underwent a lactulose breath test to diagnose SIBO. Plasma levels of warfarin and vitamin K-analogues were also assessed. Patients with an altered breath test were 50% in the VHD group, 10% in the HD group, and none in the LD group (P=0.01). Predisposing factors to SIBO were more frequent in the VHD group, while warfarin interfering variables were not. VHD patients were younger and had a higher plasma vitamin K1 (VK1) concentration (P>0.05). On the contrary, the plasma VK2 levels tended to be lower. This pilot study suggests that SIBO may increase a patient's warfarin dose requirement by increasing dietary VK1 absorption through the potentially damaged intestinal mucosa rather than increasing intestinal VK2 biosynthesis. Larger studies are needed to confirm these preliminary data and to evaluate the effects of SIBO decontamination on warfarin dosage.


Subject(s)
Intestine, Small/microbiology , Warfarin/administration & dosage , Adult , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Anticoagulants/pharmacology , Anticoagulants/therapeutic use , Bacteria/drug effects , Breath Tests , Cohort Studies , Drug Interactions , Female , Humans , International Normalized Ratio , Intestinal Mucosa/drug effects , Lactulose , Male , Middle Aged , Pilot Projects , Vitamin K/administration & dosage , Vitamin K 1/pharmacology , Warfarin/pharmacology
11.
J Nutr ; 137(10): 2270-8, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17885010

ABSTRACT

Most studies of soy and cholesterol have tested foods made from purified soy proteins containing mainly isoflavone glycosides. Fermented soy foods have mainly isoflavone aglycons and account for a high proportion of the soy protein source in Asia, where there is an inverse relationship between soy intake and serum cholesterol. The aim of this study was to compare a novel soy germ pasta, naturally enriched in isoflavone aglycons as a result of the manufacturing process, with conventional pasta for effects on serum lipids and other cardiovascular risk markers. In this randomized, controlled, parallel study design of 62 adults with hypercholesterolemia who consumed a Step II diet that included one 80-g serving/d of pasta, we measured serum lipids, high sensitivity C-reactive protein (hsCRP), urinary isoprostanes, and brachial artery flow-mediated vasodilatation at baseline and after 4 and 8 wk. The pasta delivered 33 mg of isoflavones and negligible soy protein and led to a serum isoflavone concentration of 222 +/- 21 nmol/L; 69% of subjects were equol producers. Soy germ pasta reduced serum total and LDL cholesterol by 0.47 +/- 0.13 mmol/L (P = 0.001) and 0.36 +/- 0.10 mmol/L (P = 0.002) more than conventional pasta, representing reductions from baseline of 7.3% (P = 0.001) and 8.6% (P = 0.002), respectively. Arterial stiffness (P = 0.003) and hsCRP (P = 0.03) decreased and improvements in all the above risk markers were greatest in equol producers. All measures returned to baseline when patients were switched to conventional pasta. In conclusion, pasta naturally enriched with isoflavone aglycons and lacking soy protein had a significant hypocholesterolemic effect beyond a Step II diet and improved other cardiovascular risk markers.


Subject(s)
Cardiovascular Diseases/blood , Cardiovascular Diseases/metabolism , Food, Fortified , Glycine max/chemistry , Isoflavones/chemistry , Isoflavones/pharmacology , Lipids/blood , Biomarkers/blood , Cross-Over Studies , Female , Humans , Male , Middle Aged , Risk Factors
12.
Eur J Gastroenterol Hepatol ; 18(5): 507-10, 2006 May.
Article in English | MEDLINE | ID: mdl-16607145

ABSTRACT

BACKGROUND: Although it is known that colon motility is abnormal in ulcerative colitis, data are still scarce with regard to the underlying mechanisms. Recent evidence suggests that the propulsive activity is highly increased during the active phase of the disease, probably contributing to the diarrhoea. However, data are even scarcer in the quiescent phase of the disease. AIMS: To assess the colonic high-amplitude and low-amplitude propulsive activity and the colonic motor response to eating in patients with ulcerative colitis in remission. PATIENTS AND METHODS: Fourteen patients were recruited, all with the disease in remission as documented by clinical and endoscopic criteria. Twenty-four hour manometric recordings were obtained in these patients, and compared to those of 16 healthy controls. RESULTS: The high-amplitude propagated contractions were similar in both groups (5.8+/-2.6 events in ulcerative colitis patients and 5.5+/-0.8 in controls (P=0.13)), whereas patients tended to display a higher number of low-amplitude propagated events (134.4+/-34 vs. 60.9+/-16 in controls (P=0.058)). No differences were found in the colonic motor response to eating between patients and controls. CONCLUSIONS: Colonic propulsive activity in ulcerative colitis in remission is almost normal, even though the low-amplitude propagated activity tends to be similar to that observed in patients with the irritable bowel syndrome, thus possibly contributing to the persistence of abdominal symptoms in a subgroup of patients.


Subject(s)
Colitis, Ulcerative/physiopathology , Colon/physiopathology , Eating/physiology , Gastrointestinal Motility/physiology , Adult , Defecation/physiology , Female , Humans , Male , Manometry/methods , Middle Aged , Muscle Contraction/physiology
13.
Toxicol Appl Pharmacol ; 214(2): 199-208, 2006 Jul 15.
Article in English | MEDLINE | ID: mdl-16487557

ABSTRACT

3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), the 7alpha-fluorine analog of hyodeoxycholic acid (HDCA), was synthesized to improve bioavailability and stability of ursodeoxycholic acid (UDCA). Acute rat biliary fistula and chronic cholestasis induced by 17alpha-ethynyl-estradiol (17EE) models were used to study and compare the effects of UPF-680 (dose range 0.6-6.0 micromol/kg min) with UDCA on bile flow, biliary bicarbonate (HCO(3)(-)), lipid output, biliary bile acid composition, hepatic enzymes and organic anion pumps. In acute infusion, UPF-680 increased bile flow in a dose-related manner, by up to 40.9%. Biliary HCO(3)(-) output was similarly increased. Changes were observed in phospholipid secretion only at the highest doses. Treatment with UDCA and UPF-680 reversed chronic cholestasis induced by 17EE; in this model, UDCA had no effect on bile flow in contrast to UPF-680, which significantly increased bile flow. With acute administration of UPF-680, the biliary bile acid pool became enriched with unconjugated and conjugated UPF-680 (71.7%) at the expense of endogenous cholic acid and muricholic isomers. With chronic administration of UPF-680 or UDCA, the main biliary bile acids were tauro conjugates, but modification of biliary bile acid pool was greater with UPF-680. UPF-680 increased the mRNA for cytochrome P450 7A1 (CYP7A1) and cytochrome P450 8B (CYP8B). Both UDCA and UPF-680 increased the mRNA for Na(+) taurocholate co-transporting polypeptide (NCTP). In conclusion, UPF-680 prevented 17EE-induced cholestasis and enriched the biliary bile acid pool with less detergent and cytotoxic bile acids. This novel fluorinated bile acid may have potential in the treatment of cholestatic liver disease.


Subject(s)
Cholanes/pharmacology , Cholestasis/prevention & control , Deoxycholic Acid/analogs & derivatives , Ethinyl Estradiol/toxicity , Steroids, Fluorinated/pharmacology , Animals , Bile/chemistry , Bile/drug effects , Bile Ducts/drug effects , Bile Ducts/metabolism , Cholanes/administration & dosage , Cholanes/chemistry , Cholestasis/chemically induced , Cholestasis/metabolism , Cholesterol 7-alpha-Hydroxylase/genetics , Cholesterol 7-alpha-Hydroxylase/metabolism , Chromatography, High Pressure Liquid , Deoxycholic Acid/administration & dosage , Deoxycholic Acid/chemistry , Deoxycholic Acid/pharmacology , Dose-Response Relationship, Drug , Ethinyl Estradiol/antagonists & inhibitors , Gas Chromatography-Mass Spectrometry , Male , Micelles , Molecular Structure , Phospholipids/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Steroid 12-alpha-Hydroxylase/genetics , Steroid 12-alpha-Hydroxylase/metabolism , Steroids, Fluorinated/administration & dosage , Steroids, Fluorinated/chemistry , Ursodeoxycholic Acid/administration & dosage , Ursodeoxycholic Acid/pharmacology
14.
Anticancer Res ; 24(2C): 1255-60, 2004.
Article in English | MEDLINE | ID: mdl-15154656

ABSTRACT

BACKGROUND: Low serum retinol and hepatic tocopherol levels correlate with hepatocellular carcinoma (HCC) risk. Antiestrogen tamoxifen seems useful in HCC patients. A pilot study was performed to evaluate the effect of all-trans retinoic acid associated with tamoxifen and vitamin E on patients with advanced HCC. PATIENTS AND METHODS: Fifteen consecutive patients with advanced HCC were included in the study. Patients were evaluated for survival, quality of life, liver function, tumor mass, toxicity related to the treatment and retinoid receptors in liver biopsies. RESULTS: The median survival of our patients was 22 months. Pain and asthenia were improved in the majority of patients. Every patient with baseline elevated liver enzymes showed an improvement in liver function. RAR-alpha, RXR-alpha, RAR-beta and RAR-gamma receptors were demonstrated in 100%, 73%, 47% and 40%, respectively. CONCLUSION: A combination therapy of all-trans retinoic acid, tamoxifen and vitamin E increases the survival rate and ameliorates the clinical outcome in patients with inoperable HCC.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Female , Humans , Male , Middle Aged , Pilot Projects , Tamoxifen/administration & dosage , Tamoxifen/adverse effects , Tretinoin/administration & dosage , Tretinoin/adverse effects , Vitamin E/administration & dosage , Vitamin E/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...